Myelofibrosis - Pipeline Insight, 2021

DelveInsights, Myelofibrosis - Pipeline Insight, 2021, report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Myelofibrosis Understanding
Myelofibrosis: Overview
Myelofibrosis is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. It is considered as a form of chronic leukemia. When myelofibrosis occurs on its own, it is called as primary myelofibrosis. If the disease occur as the result of a separate disease, it is known as secondary myelofibrosis. One characteristic of myelofibrosis is the overproduction of giant cells called megakaryocytes. Risk factors for myelofibrosis include exposure to ionizing radiation or to petrochemicals, such as benzene or toluene. The diagnosis of myelofibrosis include physical examination, blood tests, imaging tests, bone marrow examination, and gene tests to look for gene mutations in blood cells that are associated with myelofibrosis. Myelofibrosis treatment usually depends on the types of symptoms. Jakafi (ruxolitinib) is the first drug approved by the Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis.

"Myelofibrosis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myelofibrosis pipeline landscape is provided which includes the disease overview and Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Myelofibrosis.

Myelofibrosis Emerging Drugs Chapters
This segment of the Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myelofibrosis Emerging Drugs
Parsaclisib: Incyte Corporation
Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3K). The drug is in Phase III clinical evaluation in combination with Ruxolitinib for the treatment of myelofibrosis.

KER-050: Keros Therapeutics
KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF- receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF- family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. The drug is in Phase II clinical studies for the treatment of Myelofibrosis.
Further product details are provided in the report..

Myelofibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Myelofibrosis
There are approx. 45+ key companies which are developing the therapies for Myelofibrosis. The companies which have their Myelofibrosis drug candidates in the most advanced stage, i.e. Phase III include, Incyte Corporation.

Phases
DelveInsights report covers around 45+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myelofibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Myelofibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelofibrosis drugs.

Myelofibrosis Report Insights
Myelofibrosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Myelofibrosis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Myelofibrosis drugs?
How many Myelofibrosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelofibrosis?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Myelofibrosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Myelofibrosis and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Incyte Corporation
Keros Therapeutics
Karyopharm Therapeutics
Celgene Corporation
PharmaEssentia
Novartis
Secura Bio
Pharmaxis
Novartis Oncology
AstraZeneca
Cellenkos
Jacobio Pharmaceuticals
Ohm oncology

Key Products
Parsaclisib
KER-050
Selinexor
Lenalidomide
Ropeginterferonum alfa-2b
Panobinostat
PXS-5505
Spartalizumab
Selumetinib
CK-0804
JAB-8263
OHM-581

Introduction
Executive Summary
Myelofibrosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Myelofibrosis DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Parsaclisib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
KER-050: Keros Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
PXS-5505: Pharmaxis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
CK-0804: Cellenkos
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Appendix

List Of Tables

Table 1 Total Products for Myelofibrosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Myelofibrosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available